Your session is about to expire
← Back to Search
Sacubitril-Valsartan for Heart Failure (TREAT-HF Trial)
TREAT-HF Trial Summary
This trial is testing a new heart failure medication in young adult cancer survivors.
TREAT-HF Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTREAT-HF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TREAT-HF Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My family has a history of genetic heart muscle disease.I am not taking, or can stop taking, ACE inhibitors, ARBs, NSAIDs, aliskiren, or lithium for the study.I have severe kidney disease.I was diagnosed with constrictive cardiomyopathy before starting cancer treatment.I cannot measure my blood pressure or heart rate at home.You have had serious allergic reactions to gadolinium-based contrast agents.I have heart disease that affects my daily activities.There are signs of a specific heart condition called infiltrative cardiomyopathy.I have received anthracycline chemotherapy before.My medical records clearly show my diagnosis and treatment plan.I cannot complete a heart MRI or a 6-minute walk test.I do not experience heart failure symptoms like shortness of breath or swelling.I was diagnosed with cancer at 39 years old or younger.My heart's pumping ability is reduced but still above 40%.I have not been in another study or taken experimental drugs recently.I had significant heart valve issues before starting cancer treatment.You are allergic to valsartan or sacubitril.You have consistently high levels of potassium in your blood.I have had COVID-19 or been exposed to it recently.I am under 18 years old.I had heart valve issues before starting cancer treatment.You have a serious heart problem, as determined by the doctor, except for small holes in the heart.You have a serious buildup of fluid around your heart.
- Group 1: Arm 1: Sacubitril-valsartan
- Group 2: Arm 2: Valsartan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment still available for participants of this research?
"According to clinicaltrials.gov, this research endeavour is actively signing up participants; it was originally posted on March 9th 2022 and recently updated on May 6th 2022."
In what medical conditions is Sacubitril-valsartan most commonly prescribed?
"Sacubitril-valsartan is typically prescribed to treat certain types of ventricular dysfunction, as well as essential hypertension that cannot be successfully managed using a single therapy. It can also serve prophylactically against cardiovascular events."
Is participation in this medical study open to those under the age of 25?
"To be eligible for this research, potential participants must fall between the age of 18 and 120. Concomitantly, 23 clinical trials are available to those under 18 years old, while 720 studies can accomodate individuals over 65."
What is the current participation rate of this research project?
"Indeed, according to the clinicaltrials.gov website, this medical trial is still in need of volunteers. It was first advertised on March 9th 2022 and has been recently updated as of May 6th 2022. The study requires 30 individuals from one location."
What criteria must be fulfilled to join this medical research trial?
"The requirements for admission into this heart failure trial necessitate that patients are between 18 and 120 years old. The investigators hope to admit a total of 30 individuals."
Have researchers conducted any prior research into the efficacy of Sacubitril-valsartan?
"At present, there are 37 studies being conducted pertaining to Sacubitril-valsartan. Of those active clinical trials, 8 have reached phase 3 status. While a majority of these investigations can be found in Montreal, Quebec, global participation serves as a testament to the reach and efficacy of this medication with 826 sites running related experiments."
Share this study with friends
Copy Link
Messenger